GlassScriptPhysician profile
Katrina Agito
NPI 1306157474
$4,150.24
in general payments reported to CMS, 2019-2025
33 companies · $1,376 in 2025
The $1,376 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,640 · 2020: $333 · 2022: $233 · 2023: $174 · 2024: $393 · 2025: $1,376.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,944.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,943.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,094.38 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Sanofi-Aventis U.S. LLC | $790.56 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $237.22 | 2023-2025 | |
| Abbvie INC. | $177.78 | 2019-2025 | |
| Lilly USA, LLC | $167.72 | 2019-2025 | Mounjaro, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $137.32 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $128.50 | 2019-2020 | |
| Tandem Diabetes Care, INC. | $104.28 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Dexcom, INC. | $96.72 | 2019-2024 | Dexcom G6 Transmitter |
| Madrigal Pharmaceuticals | $90.93 | 2025 | Rezdiffra |
| Genzyme Corporation | $90.00 | 2019 | |
| Amneal Pharmaceuticals LLC | $88.08 | 2025 | Unithroid |
| Medtronic Minimed, INC. | $81.74 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $78.26 | 2025 | Gvoke Hypopen |
| Amgen INC. | $78.15 | 2019-2025 | Tepezza |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $77.82 | 2019-2020 | |
| Amarin Pharma, INC. | $70.38 | 2019-2020 | |
| Recordati_rare_diseases_inc. | $68.05 | 2025 | Isturisa |
| Sequel Med Tech, LLC | $67.05 | 2025 | Twiist |
| Abbott Laboratories | $66.44 | 2019-2025 | Freestyle Libre |
| Corcept Therapeutics | $58.24 | 2020-2025 | Korlym |
| Radius Health, INC. | $50.56 | 2025 | Tymlos |
| Cequr Corporation | $50.42 | 2025 | Cequr Simplicity |
| Almatica Pharma LLC | $47.15 | 2024-2025 | Teriparatide |
| Merck Sharp & Dohme LLC | $26.85 | 2019 | |
| Beta Bionics, INC. | $22.30 | 2024 | Ilet Bionic Pancreas |
| Ascensia Diabetes Care US INC. | $20.02 | 2024 | |
| Novartis Pharmaceuticals Corporation | $17.05 | 2024 | |
| Kyowa Kirin, INC. | $15.78 | 2024 | Crysvita |
| Medtronic, INC. | $13.63 | 2025 | Minimed 780g |
| Horizon Therapeutics Plc | $12.76 | 2023 | Tepezza |
| Kvk-Tech, INC. | $12.64 | 2019 | |
| Alexion Pharmaceuticals, INC. | $11.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katrina Agito listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.